Related Experiment Video

Updated: May 3, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic

Ion Cristóbal1, Rebeca Manso, Raúl Rincón

  • 1Authors' Affiliations: Translational Oncology Division, Health Research Institute and Oncology Department, University Hospital "Fundación Jiménez Díaz," Autonomous University of Madrid; Pathology Department, IIS "Fundación Jiménez Díaz," Madrid, Spain; and Medical Oncology Department, University Hospital of Vigo, Vigo, Spain.

Molecular Cancer Therapeutics
|January 23, 2014
PubMed

Insights

Protein phosphatase 2A (PP2A) is often inactive in colorectal cancer. Restoring PP2A activity with FTY720 shows promise as a novel therapeutic strategy, enhancing chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein phosphatase 2A (PP2A) is a critical tumor suppressor involved in cell transformation.
  • Reduced PP2A activity is a common finding in various cancers, including colorectal cancer.
  • PP2A dysregulation presents a potential therapeutic target in oncology.

Purpose of the Study:

  • To investigate the role of PP2A inactivation in colorectal cancer.
  • To explore PP2A restoration as a therapeutic strategy for colorectal cancer.
  • To evaluate the efficacy of FTY720 in combination with standard chemotherapeutic agents.

Main Methods:

  • Analysis of PP2A activity and its regulatory proteins in colorectal cancer patient samples.
  • Treatment of colorectal cancer cells with FTY720 to assess effects on proliferation, apoptosis, and signaling pathways (AKT, ERK1/2).
  • Combination studies of FTY720 with 5-fluorouracil, SN-38, and oxaliplatin.

Main Results:

  • PP2A is frequently inactivated in colorectal cancer, linked to increased SET/CIP2A and decreased PPP2R2A/PPP2R5E.
  • FTY720 treatment inhibited colorectal cancer cell proliferation and clonogenic potential.
  • FTY720 induced apoptosis and modulated AKT and ERK1/2 signaling, showing additive effects with chemotherapy drugs.

Conclusions:

  • PP2A inactivation is a common event in colorectal cancer.
  • Restoring PP2A activity with FTY720 demonstrates anti-cancer effects in colorectal cancer models.
  • FTY720, as a PP2A activator, represents a potential novel therapeutic approach for colorectal cancer, possibly enhancing existing treatments.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K